Differences in the Clinical and Hematological Characteristics of COVID-19 Patients with and without Type 2 Diabetes

Abstract EN

Objective.

To examine whether comorbidity with type 2 diabetes (T2D) affects the clinical and hematological parameters of coronavirus disease 2019 (COVID-19) patients.

Methods.

We retrospectively investigated the clinical, imaging, and laboratory characteristics of patients with confirmed COVID-19 who were hospitalized from January 30, 2020 to March 17, 2020, at the Renmin Hospital of Wuhan University.

A detailed clinical record was kept for each subject, including the medical history of COVID-19 and physical and laboratory examinations.

A total of 164 subjects were eligible for the study, among which 40 patients were comorbid with T2D.

Further analysis was conducted in two subcohorts of sex- and age-matched patients with and without T2D to identify hematological and biochemical differences.

The laboratory tests, including routine blood tests, serum biochemistry, and coagulation function, were performed upon admission.

Results.

The two groups showed no significant differences in baseline parameters, including age, sex, chest X-ray, or computed tomography (CT) findings, upon admission.

However, patients with T2D showed an increased incidence of diarrhea.

T2D patients required more recovery time from pneumonia, as shown by follow-up CT findings, which might contribute to the prolonged hospitalization.

Comorbidity with T2D also increased risk of secondary bacterial infection during COVID-19.

The T2D group had significantly higher white blood cell and neutrophil counts compared with the nondiabetic group, but T2D patients suffered from more severe lymphocytopenia and inflammation (P<0.05).

Most biochemical parameters showed no significant differences between the two groups (P>0.05).

However, patients with T2D seemed to have a significantly higher risk of developing hyperlactatemia, hyponatremia, and hypocalcemia.

Conclusions.

COVID-19 patients comorbid with T2D demonstrated distinguishing clinical features and hematological parameters during the infection.

It is necessary to develop a different clinical severity scoring system for COVID-19 patients with T2D.

This study may provide helpful clues for the assessment and management of COVID-19 in T2D patients.